NOVEL

Reproductive Sciences Ltd (RSL) has an exclusivity agreement with its subsidiary in Israel, Fertiligent, to sell EVIE® worldwide. EVIE® is a patented medical device providing a unique and innovative first line fertility treatment called Slow Release Insemination (SRI).

Trials completed in 2017 indicate that SRI can increase pregnancy success rates by 2.6x in women when compared with traditional intra-uterine insemination (IUI).

IUI is the standard first-line fertility treatment most frequently used worldwide prior to patients being recommended to try IVF. SRI is believed by RSL to be the first major development in IUI since the 1950s.

In time, the Company believes that EVIE® may be able to capture a significant share of the current IUI market (c.5m treatments a year), and eventually part of the IVF patient market segment (being much cheaper than IVF).

RSL have a clear route to market, with sales via clinical referrals (there are currently around 3,000 fertility centres worldwide, a focused market that can pursued).

EVIE® is fully developed and patented (US Patent number 8088105, European Patent number 1742685) and has already received European and US marketing approval (CE and FDA 510(k)).

A new and experienced management team has been bought in so that EVIE® can be taken to this market.

FIND YOUR LOCAL
CLINIC

Click Here

DOWNLOAD OUR MARKETING LITERATURE

PatientsClinicians

Image result for video camera icon

SEE OUR PRODUCT
VIDEO

Click Here